Kaitlin E. Schrote
Notre Dame of Maryland University
7 Papers
Kaitlin E. Schrote is an academic researcher from Notre Dame of Maryland University. The author has contributed to research in topics: Chemistry & Coagulation (water treatment). The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Surface and structural characterization of multi-walled carbon nanotubes following different oxidative treatments
Kevin A. Wepasnick,Billy Smith,Kaitlin E. Schrote,Hannah K. Wilson,Stephen R. Diegelmann,D. Howard Fairbrother +5 more
TL;DR: In this article, six commonly used wet chemical oxidants were evaluated in terms of their effects on the surface chemistry and structure of MWCNTs using a combination of analytical techniques, including X-ray photoelectron spectroscopy (XPS) and energy dispersive spectrograph (EDX).
719
Colloidal Properties of Aqueous Suspensions of Acid-Treated, Multi-Walled Carbon Nanotubes
Billy Smith,Kevin A. Wepasnick,Kaitlin E. Schrote,A R Bertele,William P. Ball,Charles R. O'Melia,D. Howard Fairbrother +6 more
TL;DR: In this article, the authors studied the influence of pH and electrolytes on the colloidal stability of oxidized multiwalled carbon nanotubes (O-MWCNTs), prepared by refluxing pristine MWCNTs in nitric acid.
224
Influence of surface oxides on the colloidal stability of multi-walled carbon nanotubes: a structure-property relationship.
Billy Smith,Kevin A. Wepasnick,Kaitlin E. Schrote,Hyun-Hee Cho,William P. Ball,D. Howard Fairbrother +5 more
TL;DR: Quantitative relationships can be developed to rationalize the influence of surface chemistry on the behavior of nanomaterials in aquatic environments and reveal that carboxylic acid groups playing the most important role are highlighted.
Association of 12-Month Contraceptive Supply Policy and Months of Contraception Prescribed by Obstetrician-Gynecologist Physicians [A01]
TL;DR: The majority of physicians were unaware of 12-month contraceptive supply policies and unable to correctly write a prescription for 12 months of contraception, suggesting physician education may be needed to effectively implement 12- month contraceptive supply Policies and meaningfully impact contraception access.
Naloxone Prescribing and Naloxone Administration in Response to Overdose Events Among Women With Opioid Use Disorder During Pregnancy and Postpartum Period - MAT-LINK, Seven Clinical Sites, 2014-2021.
Kaitlin E. Schrote,Amy Board,Pierre-Olivier Cote,Kathryn Miele,Mishka Terplan,Neil S Seligman,Pilar M. Sanjuan,Marcela C Smid,Mei Elansary,Kara M Rood,Autumn Davidson,Anthony Kendle +11 more
Abstract: OBJECTIVES
Opioid use disorder (OUD) and overdose among pregnant and postpartum women pose severe risks to maternal and infant health. Naloxone, a life-saving opioid antagonist, effectively reverses opioid overdoses but remains underutilized in this population. We examined naloxone prescription or receipt and administration during overdose events among perinatal women with OUD from the MATernaL and Infant Clinical NetworK (MAT-LINK).
METHODS
We analyzed data collected through 7 MAT-LINK clinical sites from pregnant women with OUD and known pregnancy outcomes between January 1, 2014 and August 31, 2021. Outcomes included naloxone prescriptions and naloxone administration during overdose events during pregnancy or within 12 months postpartum (perinatal period). Weighted prevalence estimates and confidence intervals were calculated by demographic characteristics, substances involved in overdoses, and receipt of medications for opioid use disorder (MOUD).
RESULTS
Only 3.1% of women received a naloxone prescription during the perinatal period; the percentage of women receiving naloxone from the clinic without a prescription was unknown and not systematically captured in the data. Women experiencing overdose events most commonly were non-Hispanic, white, had public health insurance, and lived in urban areas, reflecting the demographic composition of the MAT-LINK cohort, with high co-occurrence of tobacco/nicotine (80.5%) and stimulant use disorders (59.2%). Among women who experienced an opioid-involved overdose event, 23.4% were not administered naloxone. No significant demographic differences were observed by naloxone administration.
CONCLUSIONS
These findings highlight the need for further investigation into barriers and facilitators to naloxone clinical documentation, access, and use during the perinatal period.